CEW names Unilever’s Gina Boswell 2011 Achiever of the Year in beauty
ENGLEWOOD CLIFFS, N.J. — Unilever’s Gina Boswell, who was recently appointed EVP personal care for North America, has been selected as a 2011 Achiever of the Year, one of the highest awards bestowed in the beauty industry, by nonprofit Cosmetic Executive Women.
This year’s honorees will be feted Oct. 14 at the Waldorf Astoria in New York.
Formerly as president of global brands for Alberto-Culver, Boswell oversaw all global brands for the company, including Tresemmé, Nexxus, St. Ives and Noxzema, as well as marketing, research and development, package design and consumer insights. Unilever acquired Alberto-Culver in May 2011.
In her new role, Boswell is responsible for all brand and marketing activities for the $4.5 billion personal care portfolio, which is made up of hair care, deodorant, skin cleansing and skin care categories.
“I am thrilled to have been selected as one of this year’s honorees among some of the cosmetics industry’s most talented women,” Boswell said. "I’m personally inspired by each of these individuals and so proud of the impact we all make on the industry and the example we set as women leaders."
The CEW Achiever Awards were established in 1975 to honor leading women executives who have contributed significantly to the growth of the beauty industry and the advancement of women. The CEW board of governors votes on honorees annually, and awards are presented at the Achiever Awards event.
Previously, Boswell was recognized as one of the top 15 women in business by the Forte Foundation and Pink Magazine. She also serves on the board of directors for Manpower and the YMCA of the USA, and she was named a Henry Crown Fellow of the Aspen Institute in 2005.
Study: People with optimal levels of vitamin D have lower diabetes incidence
NEUHERBERG, Germany — Scientists at the Helmholtz Zentrum München have shown that people with good vitamin D status have a lower risk of developing Type 2 diabetes, according to a study released Sept. 30.
The study, carried out in collaboration with the German Diabetes Center in Düsseldorf and the University of Ulm, will be published in the October issue of the journal Diabetes Care.
New research on participants of the study by the Cooperative Health Research in the Region of Augsburg (KORA) has shown that people with good vitamin D status have a lower risk of developing Type 2 diabetes. Inversely, people with too low levels of vitamin D in the blood have an elevated risk. This effect may be partly due to the anti-inflammatory effect of vitamin D, the authors reported.
“Vitamin D deficiency is relatively common in Germany because of modern lifestyle factors and the geographic latitude," stated Barbara Thorand of the Institute of Epidemiology II of Helmholtz Zentrum München. "Especially during the winter months, vitamin D levels are often inadequate due to the lack of sunlight,” she noted. “If follow-up studies confirm our findings, a targeted improvement of the vitamin D status of the population could also reduce the risk of diabetes.” More than 6 million people in Germany have Type 2 diabetes, the number of undiagnosed cases could be equally high, the report noted.
Lilly’s Cialis approved for benign prostatic hyperplasia
INDIANAPOLIS — The Food and Drug Administration has approved a new use for a drug made by Eli Lilly for erectile dysfunction, Lilly said Friday.
The FDA approved Cialis (tadalafil) as a once-daily treatment for men with erectile dysfunction and benign prostatic hyperplasia, also known as BPH, as well as for BPH alone. BPH is a condition in which the prostate enlarges, which can cause urinary symptoms.
"Since many men who have ED also experience the signs and symptoms of BPH, a single medication approved to treat both may be a significant therapeutic option for men and physicians," University of Texas Southwestern Medical Center Department of Urology chairman Claus Roehrborn said. "The FDA approval of Cialis for once-daily use for the treatment of ED and the signs and symptoms of BPH provides a new option that allows men to treat both with one daily medication."